Bisphosphonate therapy for bone loss in patients with osteoporosis and periodontal disease: Clinical perspectives and review of the literature

Quintessence International

Volumn 37, Issue 2, 2006, Pages 103-107

  Palomo, Leena ^a   Bissada, Nabil ^a   Liu, James ^b,c  

^a CASE WESTERN RESERVE UNIVERSITY   (United States)

^b UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

^c CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Bisphosphonate therapy; Osteoporosis; Periodontal disease

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE;

HUMAN; OSTEOPOROSIS; PERIODONTAL DISEASE; REVIEW;

DIPHOSPHONATES; HUMANS; OSTEOPOROSIS; PERIODONTAL DISEASES;

EID: 31144469346     PISSN: 00336572     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (36)

1. Melton LJ. How many women have osteoporosis now? J Bone Miner Res 1995;10:175-177.
2. National Institutes of Arthritis and Musculoskeletal Skin Diseases. Osteoporosis Research, Education and Health Promotion. US Department of Health and Human Services, NIH publication 91-371261991. Government Printing Office, 1991.
3. Giuliani N, Pedrazzoni M, Passeri G, Girasole G. Bisphosphonates inhibit IL-6 production by human osteoblast-like cells. Scand J Rheumatol 1998;27: 38-41.
4. Reinhart RA, Payne JB, Maze CA. Influence of estrogen and osteopenia/osteoporosis on clinical periodontitis in postmenopausal women. J Periodontol 1999;70:823-828.
5. Krejci C, Bissada NF. Periodontitis - Risks for its development. Gen Dent 2000;48:430-436.
6. Tezal M, Wactawske-Wende J, Grossi SG. The relationship between bone mineral density and periodontitis in postmenopausal women. J Periodontol 2000;71:1492-1498.
7. von Wowern N, Klausen B, Kollerup G. Osteoporosis: A risk factor in periodontal disease. J Periodontol 1994;65:1134-1138.
8. Hildebolt CF. Osteoporosis and oral bone loss. Dentomaxillofac Radiol 1997;26:3-15.
9. Pilgrim TK, Hildebolt CF, Yokoyama N. Relationships between longitudinal alveolar bone height and probing depth measurements. J Periodontol 1999;70:829-833.
10. Rodan GA. Mechanisms of action of bisphosphonates. Annu Rev Pharmacol Toxicol 1998;38: 375-388.
11. Rogers MJ, Gordon S, Benford HL, et al. Cellular and molecular mechanisms of action of bisphosphonates. Cancer 2000;88:2961-2978.
12. Sato M, Grasser W. Effects of bisphospnonate on isolated rat osteoclasts as examined by reflected light microscopy. J Bone Miner Res 1990;5:31-40.
13. Hughes DE, MacDonald B, Russell RG, Gowen M. Inhibition of osteoclast-like cell formation by bisphosphonates in long-term cultures of human bone marrow. J Clin Invest 1989;83:1930-1935.
14. Hughes DE, Wright KR, Uh HL, et al. Bisphosphonates promote apoptosis in murine osteoclasts in vitro and in vivo. J Bone Miner Res 1995;10: 1478-1487.
15. Vitte C, Fleisch H, Guenther HL. Bisphosphonates induce osteoblasts to secrete an inhibitor of osteoclast-mediated resorption. Endocrinol 1996;137: 2324-2333.
16. Colucci S, Minielli B, Zanbonin G, et al. Alendronate reduces adhesion of human osteoclast-like cells to bone and bone protein-coated surfaces. Calcif Tissue Int 1998;63:230-235.
17. Fleisch H. Mechanisms of action of the bisphosphonate. Medicina 1997;57:65-75.
18. Chavassieux PM, Arlot ME, Reda C, Wei L, Yates AJ, Meunier PJ. Histomorphometric assessment of the long-term effects of alendronate on bone quality and remodeling in patients with osteoporosis. J Clin Invest 1997;6:1475-1480.
19. Devogelaer JP, Broll H, Correa-Rotter R. Oral alendronate induces progressive increases in bone mass of the spine, hip, and total body over 3 years in postmenopausal women with osteoporosis. Bone 1996;18:141-150.
20. Brunsvold MA, Chaves ES, Kornman KS, Aufdemort TB, Wood R. Effects of a bisphosphonate on experimental periodontitis in monkeys. J Periodontol 1992;63:825-830.
21. Reddy MS, Weatherford TW III, Smith CA, West BD, Jeffcoat JK. Alendronate treatment of naturally occurring periodontitis in beagle dogs. J Periodontol 1995;66:211-217.
22. Weinreb M, Quartuccio H, Seedor JG, et al. Histomorphometrical analysis of the effects of the bisphosphonate alendronate on bone loss caused by experimental periodontitis in monkeys. J Periodontal Res 1994;29:35-40.
23. Adami S, Bhalla AK, Dorizzi R, Montesanti F, Salvagno G, LoCascio V. The acute phase response after bisphosphonate administration. Calcif Tissue Int 1987;41:326-341.
24. Schweitzer DH, Oostendorp van de Ruit M, Vander Pluijm G, Lowik CW, Papapoulos SE. Interleukin-6 and acute phase response during treatment of patients with Paget's disease with the nitrogen-containing bisphosphonate dimethylaminohydroxypropylidene bisphosphonate. J Bone Miner Res 1995;10:956-962.
25. Yaffe A, Golomb G, Breuer E, Binderman I. The effect of topical delivery of novel bisacylphosphonates in reducing alveolar bone loss in the rat model. J Periodontol 2000;71:1607-1612.
26. Adachi H, Igarashi K, Mitani H, Shinoda H. Effects of topical administration of bisphosphonate (risedronate) on orthodontic tooth movement in rats. J Dent Res 1994;73:1478-1486.
27. Igarashi K, Adachi H, Mitani H, Shinoda H. Inhibitory effect of the topical administration of a bisphosphonate on root resorption incident to orthodontic tooth movement in rats. J Dent Res 1996;75: 1644-1649.
28. Meraw S, Reeve C, Wollan P. Use of alendronate in peri-implant defect regeneration. J Periodontol 1999;70:151-158.
29. Jeffcoat MK, Reddy MS. Alveolar bone loss and osteoporosis: Evidence for a common mode of therapy using the bisphosphonate alendronate. In: Davidovitch Z, Norton L (eds). The Biologic Mechanism of Tooth Resorption and Replacement by Implants. Boston: Harvard Society for the Advancement of Orthodontics, 1996:365-373.
30. El-Shinnawi UM, El-Tantawy SI. Effect of alendronate sodium on alveolar bone loss in periodontitis. J Int Acad Periodontol 2003;5:5-10.
31. Palomo L, Bissada NF, Liu J. Periodontal assessment of postmenopausal women receiving bisphosphonate therapy. Menopause (in press).
32. Rocha ML, Malacara JM, Sanchez-Marin FJ, Vazquez de la Torre CJ, Fajardo M. Effect of alendronate on periodontal disease in postmenopausal women: A randomized placebo-controlled trial. J Periodontol 2004;75:1579-1585.
33. Ruggiero SL, Mehrotra B, Rosenberg TJ, Engroff SL. Osteonecrosis of the jaws associated with the use of bisphosphonates: A review of 63 cases. J Oral Maxillofac Surg 2004;62:527-534.
34. Cranney A, Guyatt G, Griffith L. Summary of meta-analyses of therapies for postmenopausal osteoporosis. Endocr Rev 2002;23:570-578.
35. Fosamax prescribing information. In: Physicians' Desk Reference, ed 58. Montvale, NJ: Medical Economics, 2004:1986-1992.
36. Bone HG, Santora AC. Ten years of alendronate treatment for osteoporosis in postmenopausal women. Authors Reply. N Engl J Med 2004;351:191-192.